TABLE 6.

Vaccine efficacy data for eight acellular pertussis vaccines evaluated in seven trials carried out in the 1990s

Location (reference)DesignVaccine usedSchedule% Efficacy
Typical pertussisMild and typical pertussis
Sweden (Göteborg)a (768)Double-blind prospective cohortCertiva3 doses (3, 5, 12 mo)7154
Sweden (Stockholm)a (310)Double-blind prospective cohortSKB-23 doses (2, 4, 6 mo)5942
Daptacel8578
Italy (Rome) (293)Double-blind prospective cohortAcelluvax3 doses (2, 4, 6 mo)8471
Infanrix8471
Germany (Erlangen) (719)Prospective cohortACEL-IMMUNE4 doses (3, 4, 5, 6, 15-18 mo)8372
Germany (Mainz) (697)Household contactInfanrix3 doses (3, 4, 5 mo)8981
Germany (Munich)a,b (464)Case controlTripedia4 doses (2, 4, 6, 15-25 mo)80, 93
Senegalc (708)Household contactTriavax3 doses7431
  • a Significant observer bias occurred in this trial.

  • b Laboratory diagnosis based on culture only; 80% efficacy was against cough illness of 21 or more days, and 93% efficacy was against the WHO case definition.

  • c The 31% efficacy was based on 21 days or more of cough illness; 74% efficacy was against the WHO case definition.